Brought to you by 
BioDirection completes $4mm Series B round
29 Feb 2016
Executive Summary
BioDirection Inc. (brain injury diagnostics) completed a $4mm Series B convertible preferred stock sale to Provident Healthcare Capital (a fund affiliated with Provident Healthcare Partners) and other undisclosed investors. The financing will support ongoing development for the company's Tbit, a rapid point-of-care blood test to diagnose and gauge the severity of traumatic brain injury (TBI) that uses its Harvard-licensed biosensing nanowire technology to detect and measure, in less than 90-seconds, biomarker proteins released from the brain after an injury occurs.
Deal Industry
- In Vitro Diagnostics
-
Medical Devices
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioDirection completes $4mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice